Liron Walsh

Vice President and Head of Development - In Vivo Programs
Intellia Therapeutics, Inc.
Cambridge, Massachusetts, United States

Presentation(s):

• PB0235 - Trial-in-progress: A two-part open-label study of an in vivo CRISPR/Cas9-based coagulation factor IX targeted gene insertion therapy (REGV131-LNP1265), in participants with hemophilia B (BEYOND-9)

  Sunday, June 23, 2024
  13:45 – 14:45 ICT